MMM's Consumer segment continues to struggle with weak retail demand and no near-term relief in sight.
JNJ's Innovative Medicines unit shows a growth trend, defying Stelara LOE and the negative impact of the Part D redesign.
DUK's unit seeks a $74.8M rate hike in South Carolina to fund grid upgrades and increase the reliability of its services.
AXON sees surging demand for TASER devices and body cameras, fueling strong momentum in its Connected Devices unit.
LMT secures a $56M contract to sustain the C-5M Super Galaxy fleet, reinforcing its key role in U.S. strategic airlift operations.
GRRR's Q1 results are expected to gain on expanding geographic presence and solid demand for its AI-driven security and intelligence solutions.
Since taking office, the Trump administration has taken a number of actions to reduce investigations of white collar crime including directing the Justice Department to stop prosecutions under the Foreign Corrupt Practices Act which outlaws bribery and corruption in foreign countries, disbanding the Justice Department's Cryptocurrency Enforcement Unit and reducing the size and support of the Justice Department's Public Integrity Section which prosecutes public officials accused of corruption and the IRS' Criminal Investigation Unit. In addition, a number of white collar crime prosecutions begun under the previous administration have been dropped including an action by the Consumer Financial Protection Bureau against Capital One.
VANI is set to spin off Cortigent, aiming to sharpen its focus on drug implants and unlock long-term value for both entities.
PBR signs a EUR 250 million deal with Mota-Engil to deliver advanced offshore construction and maintenance services across key platforms in Brazil's pre-salt Santos Basin.
PBR starts up a new diesel hydrotreatment unit at REPLAN, increasing clean fuel output and advancing sustainability goals ahead of schedule.
Starz reversed recent U.S. subscriber losses in its fiscal fourth quarter, but disclosed a restructuring charge of $177.4 million due to a “reassessment” of its content portfolio.
Cigna's Evernorth business caps GLP-1 drug copays at $200 or less, aiming to boost affordability for patients and cut costs for health plan sponsors.